TP53 (rs1042522, rs28934571) and TP21 (rs1801270, rs1059234) Polymorphisms and Risk of Breast Cancer among Rural Women of Maharashtra: Findings from a Hospital Based Case- Control Study.
Genetic polymorphism
PCR-RFLP
breast cancer
p21
p53
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 May 2023
01 May 2023
Historique:
received:
05
11
2022
medline:
31
5
2023
pubmed:
29
5
2023
entrez:
29
5
2023
Statut:
epublish
Résumé
Various studies all around the world depicted the relationship of polymorphisms in tumor suppressor genes with risk of various cancers, but there are unambiguous conclusions on this association. A hospital based case-control study was designed to review the association of polymorphism of tumor suppressor genes p21 and p53 with breast cancer risk in women residing in rural Maharashtra. Two single nucleotide polymorphisms (SNPs) a C>A transversion (Ser>Arg) at codon 31 of exon 2 (rs1801270), C>T transition occurring 20bp upstream from stop codon of exon 3 (rs1059234) in p21 gene and G>C (Arg>Pro) transition at codon 72 of exon 4 (rs1042522), G>T (Arg>Ser) transition at codon 249 in exon 7 (rs28934571) in p53 gene were studied. To precise the quantitative assessment, we enrolled 800 subjects sorted into 400 clinically confirmed breast cancer patients and 400 healthy women from a tertiary care hospital (Krishna Hospital and Medical Research Centre) of south-western Maharashtra. The genetic polymorphisms in p21 and p53 genes was studied by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method using blood genomic DNA isolated from breast cancer patients and controls. The level of association of polymorphisms was assessed using Odds ratio (OR) with 95% confidence interval and p-value identified using logistic regression model. After the analysis of SNPs (rs1801270, rs1059234) of p21 and (rs1042522, rs28934571) in p53 gene our analysis suggested that heterozygote Ser/Arg genotype with OR=0.66; 95% CI: 0.47- 0.91; p=0.0003 and homozygote variant Arg/Arg genotype with OR=0.23; 95% CI: 0.13- 0.40; p<0.0001of rs1801270 of p21 was negatively associated with risk of breast cancer in studied population. The findings from this study supported that rs1801270 SNP of p21 was inversely associated with breast cancer risk in the studied rural women population.
Sections du résumé
BACKGROUND
BACKGROUND
Various studies all around the world depicted the relationship of polymorphisms in tumor suppressor genes with risk of various cancers, but there are unambiguous conclusions on this association. A hospital based case-control study was designed to review the association of polymorphism of tumor suppressor genes p21 and p53 with breast cancer risk in women residing in rural Maharashtra.
METHODS
METHODS
Two single nucleotide polymorphisms (SNPs) a C>A transversion (Ser>Arg) at codon 31 of exon 2 (rs1801270), C>T transition occurring 20bp upstream from stop codon of exon 3 (rs1059234) in p21 gene and G>C (Arg>Pro) transition at codon 72 of exon 4 (rs1042522), G>T (Arg>Ser) transition at codon 249 in exon 7 (rs28934571) in p53 gene were studied. To precise the quantitative assessment, we enrolled 800 subjects sorted into 400 clinically confirmed breast cancer patients and 400 healthy women from a tertiary care hospital (Krishna Hospital and Medical Research Centre) of south-western Maharashtra. The genetic polymorphisms in p21 and p53 genes was studied by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method using blood genomic DNA isolated from breast cancer patients and controls. The level of association of polymorphisms was assessed using Odds ratio (OR) with 95% confidence interval and p-value identified using logistic regression model.
RESULTS
RESULTS
After the analysis of SNPs (rs1801270, rs1059234) of p21 and (rs1042522, rs28934571) in p53 gene our analysis suggested that heterozygote Ser/Arg genotype with OR=0.66; 95% CI: 0.47- 0.91; p=0.0003 and homozygote variant Arg/Arg genotype with OR=0.23; 95% CI: 0.13- 0.40; p<0.0001of rs1801270 of p21 was negatively associated with risk of breast cancer in studied population.
CONCLUSION
CONCLUSIONS
The findings from this study supported that rs1801270 SNP of p21 was inversely associated with breast cancer risk in the studied rural women population.
Identifiants
pubmed: 37247280
doi: 10.31557/APJCP.2023.24.5.1611
pmc: PMC10495895
pii:
doi:
Substances chimiques
Codon
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
CDKN1A protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1611-1619Références
Curr Genomics. 2018 Aug;19(5):395-410
pubmed: 30065615
PLoS One. 2014 Apr 18;9(4):e94874
pubmed: 24747975
Indian J Med Res. 2016 Sep;144(3):314-316
pubmed: 28139528
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Asian Pac J Cancer Prev. 2014;15(24):10653-8
pubmed: 25605155
Asian Pac J Cancer Prev. 2012;13(2):511-6
pubmed: 22524816
Pathobiology. 2018;85(4):247-253
pubmed: 29949804
Biomed Rep. 2015 Sep;3(5):707-714
pubmed: 26405550
Exp Ther Med. 2013 May;5(5):1397-1402
pubmed: 23737888
Mutagenesis. 2003 Jul;18(4):377-85
pubmed: 12840112
Gastric Cancer. 2011 Aug;14(3):242-8
pubmed: 21461655
J Cancer. 2018 Sep 8;9(19):3522-3531
pubmed: 30310509
Asian Pac J Cancer Prev. 2011;12(8):1893-8
pubmed: 22292621
Chronic Dis Transl Med. 2017 May 25;3(2):95-104
pubmed: 29063062
Asian Pac J Cancer Prev. 2014;15(16):6871-9
pubmed: 25169539
Appl Clin Genet. 2011 Jan 07;4:11-9
pubmed: 23776363
PLoS One. 2016 Jul 14;11(7):e0157344
pubmed: 27415837
BMC Med Genet. 2020 Oct 19;21(1):206
pubmed: 33076844
Biosci Rep. 2019 Mar 19;39(3):
pubmed: 30833364
Indian J Med Res. 2016 Sep;144(3):359-365
pubmed: 28139534
Front Genet. 2022 Apr 27;13:807466
pubmed: 35571038
Semin Oncol. 2016 Oct;43(5):528-535
pubmed: 27899183
Pathobiology. 2018;85(3):186-191
pubmed: 29131100
Anticancer Res. 2007 May-Jun;27(3B):1559-64
pubmed: 17595776
Tumour Biol. 2014 Sep;35(9):8607-13
pubmed: 24863946
Breast Cancer Res Treat. 2019 Jun;175(2):479-485
pubmed: 30796655
Front Oncol. 2022 Aug 19;12:973077
pubmed: 36059664
PLoS One. 2020 Sep 25;15(9):e0238500
pubmed: 32976537
Front Physiol. 2018 Aug 02;9:1014
pubmed: 30116199
BMC Ophthalmol. 2005 Apr 04;5:5
pubmed: 15807891
Breast Cancer (Dove Med Press). 2019 Apr 10;11:151-164
pubmed: 31040712
Indian J Cancer. 2013 Oct-Dec;50(4):316-21
pubmed: 24369207